Literature DB >> 16304243

Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel.

Robert M Strieter1.   

Abstract

Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP) is not well-understood. Current explanations of the natural history and pathogenesis of IPF/UIP are controversial, and ongoing research continues to investigate multiple hypotheses. A complete understanding of the natural history of IPF could potentially help to identify different mechanisms that are operative at the early, intermediate, and end stages of the disease. This knowledge could lead to the development of more effective therapeutic interventions that target stage-specific aberrant pathways involved in IPF/UIP pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304243     DOI: 10.1378/chest.128.5_suppl_1.526S

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  47 in total

1.  Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis.

Authors:  William R Coward; Keira Watts; Carol A Feghali-Bostwick; Gisli Jenkins; Linhua Pang
Journal:  Mol Cell Biol       Date:  2010-04-19       Impact factor: 4.272

Review 2.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

3.  What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis.

Authors:  Robert M Strieter
Journal:  Proc Am Thorac Soc       Date:  2008-04-15

4.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

Authors:  Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson
Journal:  Am J Respir Crit Care Med       Date:  2012-01-01       Impact factor: 21.405

5.  Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin.

Authors:  Robert D Guzy; Ivan Stoilov; Timothy J Elton; Robert P Mecham; David M Ornitz
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

6.  Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis.

Authors:  Masaru Uchida; Hiroshi Shiraishi; Shoichiro Ohta; Kazuhiko Arima; Kazuto Taniguchi; Shoichi Suzuki; Masaki Okamoto; Shawn K Ahlfeld; Koichi Ohshima; Seiya Kato; Shuji Toda; Hironori Sagara; Hisamichi Aizawa; Tomoaki Hoshino; Simon J Conway; Shinichiro Hayashi; Kenji Izuhara
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-12       Impact factor: 6.914

Review 7.  Smad3 signaling involved in pulmonary fibrosis and emphysema.

Authors:  Jack Gauldie; Martin Kolb; Kjetil Ask; Gail Martin; Philippe Bonniaud; David Warburton
Journal:  Proc Am Thorac Soc       Date:  2006-11

8.  Imaging of fibrogenesis in patients with idiopathic pulmonary fibrosis with cis-4-[(18)F]-Fluoro-L: -proline PET.

Authors:  Jules Lavalaye; Jan C Grutters; Ewoudt M W van de Garde; Monique M C van Buul; Jules M M van den Bosch; Albert D Windhorst; Fred J Verzijlbergen
Journal:  Mol Imaging Biol       Date:  2008-07-30       Impact factor: 3.488

9.  WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis.

Authors:  Melanie Königshoff; Monika Kramer; Nisha Balsara; Jochen Wilhelm; Oana Veronica Amarie; Andreas Jahn; Frank Rose; Ludger Fink; Werner Seeger; Liliana Schaefer; Andreas Günther; Oliver Eickelberg
Journal:  J Clin Invest       Date:  2009-03-16       Impact factor: 14.808

10.  Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF).

Authors:  Kathy Boon; Nathaniel W Bailey; Jun Yang; Mark P Steel; Steve Groshong; Dolly Kervitsky; Kevin K Brown; Marvin I Schwarz; David A Schwartz
Journal:  PLoS One       Date:  2009-04-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.